SER EFFECT SEC Filing Analysis

Latest settled — T+5d

SER ▼ -2.69% at T+5d

SHORT call ✓ call won +2.69% · α vs SPY +0.14% · entry $1.86 → $1.81

Next anchor: T+20d in 16d

Currently $2.04 · -9.68% from $1.86 entry (call sign-flipped)

Entry anchored
Jun 4, 2026
via day open

T+1d

+1.08%

call -1.08% · α -3.67%

$1.88

settled 12d ago

T+5d

-2.69%

call +2.69% · α +0.14%

$1.81

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June 3, 2026. This shelf, filed 13 days ago, registers up to 16,450,442 shares of common stock for resale by selling stockholders, stemming from a $21.2M PIPE in March/April 2026. With ~15M shares outstanding, potential dilution exceeds 100%, and the company disclosed substantial doubt about its ability to continue as a going concern in its most recent 10-Q.

Actionable Insight

The shelf going effective opens the door for selling stockholders, including insiders, to exit their positions. With the company burning cash and expressing going-concern doubt, expect persistent overhang and likely further price pressure. Monitor for a prospectus supplement indicating an actual takedown.

Key Facts

Effectiveness date: June 3, 2026 for S-3 File No. 333-296166
Registration covers up to 16,450,442 shares for resale by selling stockholders
Shares originate from a $21.2M PIPE completed in March/April 2026
Approximately 14,997,505 shares currently outstanding — potential dilution exceeds 100%
Company disclosed substantial doubt about going concern in its most recent 10-Q (net loss -$6.9M in Q1 2026 vs -$4.8M in Q1 2025)
Selling stockholders include insider Dr. Gregory H. Bailey

Financial Impact

Potential dilution of over 100% on current ~15M shares outstanding via up to 16.45M registered shares for resale

dilutionshare price

Risk Factors

Massive dilution overhang with >100% potential share count increase
Insider selling pressure from PIPE participants including Dr. Gregory H. Bailey
Going-concern risk highlighted in recent 10-Q with widening net losses
Low market cap ($27M) amplifies impact of any secondary sales

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

83% bullish (6 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
EFFECT Filing (Primary)	9999999995-26-001872
Document: 9999999995-26-001872-index.html	9999999995-26-001872
Document: 9999999995-26-001872.txt	9999999995-26-001872

6 reports for SER

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SER — sortable, filterable
	Type				Now
Jun 4, 2026 13d ago	EFFECT BEARISH ★ 7/10	$1.86 $1.81	▲ +2.69%	▲ +0.14%	$2.04 (−9.68%)
May 26, 2026 21d ago	Insider Cluster MIXED ★ 5/10	$1.80 $1.79	▼ −0.56%	▼ −1.02%	$2.04 (+13.33%)
May 26, 2026 21d ago	Insider Cluster BEARISH ★ 5/10	$1.80 $1.79	▲ +0.56%	▲ +1.02%	$2.04 (−13.33%)
May 22, 2026 25d ago	S-3 BEARISH ★ 7/10	$1.92 $1.81	▲ +5.73%	▲ +6.81%	$2.04 (−6.25%)
Mar 27, 2026 11w ago	10-K/A NEUTRAL ★ 2/10	$2.27 $2.15	▼ −5.29%	▼ −9.15%	$2.04 (−10.13%)
Mar 25, 2026 11w ago	Press Release MIXED ★ 7/10	$2.61 $2.12	▼ −18.77%	▼ −20.41%	$2.04 (−21.84%)

US Market Status

Market Closed — Opens in 5h 42m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access